132 related articles for article (PubMed ID: 29438108)
21. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
22. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
23. STAT3 promotes bone fracture healing by enhancing the FOXP3 expression and the suppressive function of regulatory T cells.
Sun G; Wang Z; Ti Y; Wang Y; Wang J; Zhao J; Qian H
APMIS; 2017 Aug; 125(8):752-760. PubMed ID: 28493494
[TBL] [Abstract][Full Text] [Related]
24. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
25. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
Yue C; Shen S; Deng J; Priceman SJ; Li W; Huang A; Yu H
Cancer Immunol Res; 2015 Aug; 3(8):864-870. PubMed ID: 26025380
[TBL] [Abstract][Full Text] [Related]
26. Caveolin-2 deficiency induces a rapid anti-tumor immune response prior to regression of implanted murine lung carcinoma tumors.
Liu Y; Qi X; Li G; Sowa G
Sci Rep; 2019 Dec; 9(1):18970. PubMed ID: 31831780
[TBL] [Abstract][Full Text] [Related]
27. Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3.
Kowalczyk A; D'Souza CA; Zhang L
Eur J Immunol; 2014 Apr; 44(4):1143-55. PubMed ID: 24338929
[TBL] [Abstract][Full Text] [Related]
28. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.
Milner JD; Vogel TP; Forbes L; Ma CA; Stray-Pedersen A; Niemela JE; Lyons JJ; Engelhardt KR; Zhang Y; Topcagic N; Roberson ED; Matthews H; Verbsky JW; Dasu T; Vargas-Hernandez A; Varghese N; McClain KL; Karam LB; Nahmod K; Makedonas G; Mace EM; Sorte HS; Perminow G; Rao VK; O'Connell MP; Price S; Su HC; Butrick M; McElwee J; Hughes JD; Willet J; Swan D; Xu Y; Santibanez-Koref M; Slowik V; Dinwiddie DL; Ciaccio CE; Saunders CJ; Septer S; Kingsmore SF; White AJ; Cant AJ; Hambleton S; Cooper MA
Blood; 2015 Jan; 125(4):591-9. PubMed ID: 25359994
[TBL] [Abstract][Full Text] [Related]
29. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
Larmonier N; Marron M; Zeng Y; Cantrell J; Romanoski A; Sepassi M; Thompson S; Chen X; Andreansky S; Katsanis E
Cancer Immunol Immunother; 2007 Jan; 56(1):48-59. PubMed ID: 16612596
[TBL] [Abstract][Full Text] [Related]
30. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity.
Lin YC; Chang LY; Huang CT; Peng HM; Dutta A; Chen TC; Yeh CT; Lin CY
J Immunol; 2009 May; 182(10):6095-104. PubMed ID: 19414761
[TBL] [Abstract][Full Text] [Related]
31. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.
Liu JF; Ma SR; Mao L; Bu LL; Yu GT; Li YC; Huang CF; Deng WW; Kulkarni AB; Zhang WF; Sun ZJ
Mol Oncol; 2017 Feb; 11(2):235-247. PubMed ID: 28102051
[TBL] [Abstract][Full Text] [Related]
32. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
33. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
34. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
35. Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid-derived suppressor cells via TLR2-dependent STAT3 activation.
Lee JM; Kim EK; Seo H; Jeon I; Chae MJ; Park YJ; Song B; Kim YS; Kim YJ; Ko HJ; Kang CY
Eur J Immunol; 2014 Jun; 44(6):1672-84. PubMed ID: 24659444
[TBL] [Abstract][Full Text] [Related]
36. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
Zhu S; Lin J; Qiao G; Xu Y; Zou H
Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
[TBL] [Abstract][Full Text] [Related]
37. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
38. Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.
Mohammadpour H; O'Neil R; Qiu J; McCarthy PL; Repasky EA; Cao X
J Immunol; 2018 Apr; 200(7):2479-2488. PubMed ID: 29445008
[TBL] [Abstract][Full Text] [Related]
39. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.
Qu Z; Sun F; Zhou J; Li L; Shapiro SD; Xiao G
Cancer Res; 2015 Aug; 75(16):3209-15. PubMed ID: 26122841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
